Yıl: 2019 Cilt: 30 Sayı: 2 Sayfa Aralığı: 139 - 147 Metin Dili: İngilizce İndeks Tarihi: 20-05-2019

Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey

Öz:
Background/Aims: Patients with ulcerative colitis (UC) are at increased risk of colorectal cancer (CRC). High-grade dysplasia (HGD) andlow-grade dysplasia (LGD) are premalignant conditions. The aim of this study is to evaluate the risk of CRC/dysplasia in patients withUC, and the related risk factors.Materials and Methods: Medical records of 1659 patients dating between 1993 and 2016 were scanned from an inflammatory boweldisease database. A total of 801 patients with UC who underwent at least one colonoscopic procedure with at least 1-year follow-upperiod were included in the study. Clinical, endoscopic, and histopathological data were assessed.Results: The mean disease duration was 6.7±6.6 years. The total disease duration was 5334 person-years duration (pyd), and 34% ofpatients had the disease for 8 years or longer. The prevalence of UC-associated CRC was 0.7%, and the prevalence of dysplasia was0.85%. The overall incidence of CRC was determined to be 1.1/1000 pyd. The cumulative risk of CRC was 0.3% at 10 years, 1.3% at 20years, and 5.9% at 30 years. The Cox regression analysis indicated that primary sclerosing cholangitis (HR:13.677, 95% CI:2.6-70.8,p=0.012) was an independent risk factor for developing UC-associated CRC.Conclusion: This study underlined the low risk of CRC and dysplasia in patients with UC in a tertiary referral center in the western part ofTurkey. Primary sclerosing cholangitis was found to be the most important risk factor for the development of CRC in patients with UC.Identification of risk factors is important to categorize patients into subgroups to know which patients will require frequent surveillance.
Anahtar Kelime:

Konular: Gastroenteroloji ve Hepatoloji
Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık
  • Rutter M, Saunders B, Wilkinson K, et al. Severity of inflammation is a risk factor for colorectal neoplasia in ulcerative colitis. Gastroenterology 2004; 126: 451-9. [CrossRef]
  • Dyson JK, Rutter MD. Colorectal cancer in inflammatory bowel disease: what is the real magnitude of the risk? World J Gastroenterol 2012; 18: 3839-48. [CrossRef]
  • Munkholm P. Review article: the incidence and prevalence of colorectal cancer in Inflammatory bowel disease Aliment Pharmacol Ther 2003; 18(Suppl 2): 1-5. [CrossRef]
  • Garg SK, Loftus EV, Jr. Risk of cancer in inflammatory bowel disease: going up, going down, or still the same? Curr Opin Gastroenterol 2016; 32: 274-81. [CrossRef]
  • Jess T, Simonsen J, Jorgensen KT, Pedersen BV, Nielsen NM, Frisch M. Decreasing risk of colorectal cancer in patients with inflammatory bowel disease over 30 years. Gastroenterology 2012; 143: 375-81. [CrossRef]
  • Soderlund S, Brandt L, Lapidus A, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology 2009; 136: 1561-7. [CrossRef]
  • Ekbom A, Helmick C, Zack M, Adami HO. Ulcerative colitis and colorectal cancer. A population-based study N Engl J Med 1990; 323: 1228-33. [CrossRef]
  • Xie J, Itzkowitz SH. Cancer in inflammatory bowel disease World J Gastroenterol 2008; 14: 378-89. [CrossRef]
  • Soetikno RM, Lin OS, Heidenreich PA, Young HS, Blackstone MO. Increased risk of colorectal neoplasia in patients with primary sclerosing cholangitis and ulcerative colitis: a meta-analysis Gastrointest Endosc 2002; 56: 48-54. [CrossRef]
  • Askling J, Dickman PW, Karlen P, et al. Family history as a risk factor for colorectal cancer in inflammatory bowel disease Gastroenterology 2001; 120: 1356-62. [CrossRef]
  • Heuschen UA, Hinz U, Allemeyer EH, et al. Backwash ileitis is strongly associated with colorectal carcinoma in ulcerative colitis Gastroenterology 2001; 120: 841-7. [CrossRef]
  • Farraye FA, Odze RD, Eaden J, et al. AGA medical position statement on the diagnosis and management of colorectal neoplasia in inflammatory bowel disease Gastroenterology 2010; 138: 738-45. [CrossRef]
  • Leighton JA, Shen B, Baron TH, et al. ASGE guideline: endoscopy in the diagnosis and treatment of inflammatory bowel disease. Gastrointest Endosc 2006; 63: 558-65. [CrossRef]
  • Magro F, Gionchetti P, Eliakim R, et al. Third European Evidence-Based Consensus on Diagnosis and Management of Ulcerative Colitis. Part 1: Definitions, diagnosis, extra-intestinal manifestations, pregnancy, cancer surveillance, surgery, and ileo-anal pouch disorders. J Crohn’s Colitis 2017; 11: 649-70. [CrossRef]
  • Eaden JA, Abrams KR, Mayberry JF. The risk of colorectal cancer in ulcerative colitis: a meta-analysis. Gut 2001; 48: 526-35. [CrossRef]
  • Lutgens MW, van Oijen MG, van der Heijden GJ, Vleggaar FP, Siersema PD, Oldenburg B. Declining risk of colorectal cancer in inflammatory bowel disease: an updated meta-analysis of population-based cohort studies. Inflamm Bowel Dis 2013; 19: 789-99. [CrossRef]
  • Andersen NN, Jess T. Has the risk of colorectal cancer in inflammatory bowel disease decreased? World J Gastroenterol 2013; 19: 7561-8. [CrossRef]
  • Castano-Milla C, Chaparro M, Gisbert JP. Systematic review with meta-analysis: the declining risk of colorectal cancer in ulcerative colitis. Aliment Pharmacol Ther 2014; 39: 645-59. [CrossRef]
  • Ahuja N, Mohan AL, Li Q, et al. Association between CpG island methylation and microsatellite instability in colorectal cancer. Cancer Res 1997; 57: 3370-4.
  • Aktan H, Paykoc Z, Ertan A. Ulcerative colitis in Turkey: clinical review of sixty cases. Dis Colon Rectum 1970; 13: 62-5. [CrossRef]
  • Kusakcioglu O, Kusakcioglu A, Oz F. Idiopathic ulcerative colitis in Istanbul: clinical review of 204 cases. Dis Colon Rectum 1979; 22: 350-5. [CrossRef]
  • Tozun N, Atug O, Imeryuz N, et al. Clinical characteristics of inflammatory bowel disease in Turkey: a multicenter epidemiologic survey. J Clin Gastroenterol 2009; 43: 51-7. [CrossRef]
  • Ozin Y, Kilic MZ, Nadir I, et al. Clinical features of ulcerative colitis and Crohn’s disease in Turkey. J Gastrointestin Liver Dis 2009; 18: 157-62.
  • Kekilli M, Dagli U, Kalkan IH, et al. Low incidence of colorectal dysplasia and cancer among patients with ulcerative colitis: a Turkish referral centre study. Scand J Gastroenterol 2010; 45: 434-9. [CrossRef]
  • Silverberg MS, Satsangi J, Ahmad T, et al. Toward an integrated clinical, molecular and serological classification of inflammatory bowel disease: report of a Working Party of the 2005 Montreal World Congress of Gastroenterology. Can J Gastroenterol 2005; 19: 5A-36A. [CrossRef]
  • Schlemper RJ, Riddell RH, Kato Y, et al. The Vienna classification of gastrointestinal epithelial neoplasia. Gut 2000; 47: 251-5. [CrossRef]
  • Kaplan EL. Meier P. Nonparametric Estimation from Incomplete Observations. J Am Stat Assoc 1958; 53: 457-81. [CrossRef]
  • Cox DR. Regression Models and Life-Tables. J R Stat Soc Ser B 1972; 34: 187-220.
  • Kewenter J, Ahlman H, Hulten L. Cancer risk in extensive ulcerative colitis. Ann Surg 1978; 188: 824-8. [CrossRef]
  • Lyakhovich A, Gasche C. Systematic review: molecular chemoprevention of colorectal malignancy by mesalazine. Aliment Pharmacol Ther 2010; 31: 202-9.
  • Eser S, Yakut C, Ozdemir R, et al. Cancer incidence rates in Turkey in 2006: a detailed registry based estimation. Asian Pac J Cancer Prev 2010; 11: 1731-9.
  • Triantafillidis JK, Emmanouilidis A, Manousos ON, et al. Ulcerative colitis in Greece: clinicoepidemiological data, course, and prognostic factors in 413 consecutive patients. J Clin Gastroenterol 1998; 27: 204-10. [CrossRef]
  • Kountouras J, Zavos C, Chatzopoulos D. Apoptosis and apoptosis-related proteins in inflammatory bowel disease. Apoptosis 2004; 9: 657-8. [CrossRef]
  • Lakatos L, Mester G, Erdelyi Z, et al. Risk factors for ulcerative colitis-associated colorectal cancer in a Hungarian cohort of patients with ulcerative colitis: results of a population-based study. Inflamm Bowel Dis 2006; 12: 205-11. [CrossRef]
  • Gyde SN, Prior P, Allan RN, et al. Colorectal cancer in ulcerative colitis: a cohort study of primary referrals from three centres. Gut 1988; 29: 206-17. [CrossRef]
  • Soderlund S, Granath F, Brostrom O, et al. Inflammatory bowel disease confers a lower risk of colorectal cancer to females than to males. Gastroenterology 2010; 138: 1697-703. [CrossRef]
  • Aykan NF, Yalcin S, Turhal NS, et al. Epidemiology of colorectal cancer in Turkey: A cross-sectional disease registry study (A Turkish Oncology Group trial). Turk J Gastroenterol 2015; 26: 145-53. [CrossRef]
  • Li H, Jin Z, Li X, Wu L, Jin J. Associations between single-nucleotide polymorphisms and inflammatory bowel disease-associated colorectal cancers in inflammatory bowel disease patients: a meta-analysis. Clin Transl Oncol 2017; 19: 1018-27. [CrossRef]
APA ÜNAL N, Ozutemiz A, TEKİN F, TURAN I, OSMANOĞLU N (2019). Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. , 139 - 147.
Chicago ÜNAL NALAN GÜLSEN,Ozutemiz Ahmet Omer,TEKİN Fatih,TURAN ILKER,OSMANOĞLU Necla Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. (2019): 139 - 147.
MLA ÜNAL NALAN GÜLSEN,Ozutemiz Ahmet Omer,TEKİN Fatih,TURAN ILKER,OSMANOĞLU Necla Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. , 2019, ss.139 - 147.
AMA ÜNAL N,Ozutemiz A,TEKİN F,TURAN I,OSMANOĞLU N Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. . 2019; 139 - 147.
Vancouver ÜNAL N,Ozutemiz A,TEKİN F,TURAN I,OSMANOĞLU N Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. . 2019; 139 - 147.
IEEE ÜNAL N,Ozutemiz A,TEKİN F,TURAN I,OSMANOĞLU N "Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey." , ss.139 - 147, 2019.
ISNAD ÜNAL, NALAN GÜLSEN vd. "Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey". (2019), 139-147.
APA ÜNAL N, Ozutemiz A, TEKİN F, TURAN I, OSMANOĞLU N (2019). Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. Turkish Journal of Gastroenterology, 30(2), 139 - 147.
Chicago ÜNAL NALAN GÜLSEN,Ozutemiz Ahmet Omer,TEKİN Fatih,TURAN ILKER,OSMANOĞLU Necla Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. Turkish Journal of Gastroenterology 30, no.2 (2019): 139 - 147.
MLA ÜNAL NALAN GÜLSEN,Ozutemiz Ahmet Omer,TEKİN Fatih,TURAN ILKER,OSMANOĞLU Necla Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. Turkish Journal of Gastroenterology, vol.30, no.2, 2019, ss.139 - 147.
AMA ÜNAL N,Ozutemiz A,TEKİN F,TURAN I,OSMANOĞLU N Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. Turkish Journal of Gastroenterology. 2019; 30(2): 139 - 147.
Vancouver ÜNAL N,Ozutemiz A,TEKİN F,TURAN I,OSMANOĞLU N Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey. Turkish Journal of Gastroenterology. 2019; 30(2): 139 - 147.
IEEE ÜNAL N,Ozutemiz A,TEKİN F,TURAN I,OSMANOĞLU N "Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey." Turkish Journal of Gastroenterology, 30, ss.139 - 147, 2019.
ISNAD ÜNAL, NALAN GÜLSEN vd. "Colorectal cancer and dysplasia risk of ulcerative colitis patients in a tertiary referral center in Turkey". Turkish Journal of Gastroenterology 30/2 (2019), 139-147.